Loading
A phase 3 trial of Docetaxel, Doxorubicin, Estramustine, Prednisone, Vinblastine and Dexamethasone in Prostate cancer, run by M.D. Anderson Cancer Center, recorded as terminated on the registry.
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer is a phase 3 interventional study registered as NCT00024167 by M.D. Anderson Cancer Center, with 265 participants recorded, started 2002-04 and due to reach its primary completion in 2014-09. Interventions recorded: Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium, Ketoconazole, Prednisone, Vinblastine, Strontium chloride Sr 89, Dexamethasone. Conditions recorded: Prostate Cancer.
Linked to the drug Estramustine because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
265 enrolled.
95% CI 19.8 to 29.8; Figures from the ClinicalTrials.gov results section (first posted 2016-03-22), not from a publication · 95% CI 17.7 to 27.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival From Randomizationprimary | Induction Treatment + Strontium-89 | 65 | 24.2 months | - | - | link |
| Induction Treatment + No Strontium-89 | 62 | 22.8 months |
Shares Estramustine, Docetaxel, Prostate cancer and the tag pipeline.
Shares Prednisone, Dexamethasone, Docetaxel, Prostate cancer and the tag pipeline.
Shares Prednisone, Docetaxel, Prostate cancer and the tag pipeline.
Shares Estramustine, Prostate cancer and the tag pipeline.
Shares Prednisone, Dexamethasone, Doxorubicin and the tag pipeline.
Shares Vinblastine, Doxorubicin and the tag pipeline.
Shares Prednisone, Prostate cancer and the tag pipeline.
Shares Dexamethasone, Prostate cancer and the tag pipeline.